ution.
Palivizumab solution for injection does not contain a preservative, is for single use and should be administered immediately after drawing the dose into the syringe.
Any unused product or waste material should be disposed of in accordance with local requirements.
7. Marketing authorisation holder
AbbVie Deutschland GmbH & Co. KG
Knollstrasse
67061 Ludwigshafen
Germany
8. Marketing authorisation number(s)
EU/1/99/117/003
EU/1/99/117/004
9. Date of first authorisation/renewal of the authorisation
Date of first authorisation: 13 August 1999
Date of latest renewal: 13 August 2009
10. Date of revision of the text
08 May 2018
Detailed information on this product is available on the website of the European Medicines Agency: http://www.ema.europa.eu. |
